Compare Stocks

→ The #1 Opportunity of the decade? (From Behind the Markets) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NYMX Nymox Pharmaceutical		$0.34	$0.17 ▼ $0.74	$18.10M	0.64	94,622 shs	932,700 shs
RIOT Riot Platforms	$9.13 +10.1%	$12.54	$7.80 ▼ $20.65	$2.31B	4.25	25.61 million shs	25.43 million shs
VNRX VolitionRx	$0.62 -0.2%	$0.88	$0.55 ▼ $2.10	$50.56M	1.35	177,445 shs	245,613 shs

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NYMX Nymox Pharmaceutical	0.00%	0.00%	0.00%	0.00%	-53.38%
RIOT Riot Platforms	+4.02%	-14.97%	-25.25%	-19.44%	-31.54%
VNRX VolitionRx	+2.87%	-13.06%	-27.39%	-35.78%	+61,719,900.00%

Will this $2 AI stock double overnight? (Ad)

It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!

Click here to learn more >>>

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
NYMX Nymox Pharmaceutical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RIOT Riot Platforms	3.5103 of 5 stars	4.5	4.0	0.0	0.0	1.5	1.7	1.3
VNRX VolitionRx	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NYMX Nymox Pharmaceutical	N/A	N/A	N/A	N/A
RIOT Riot Platforms	3.00	Buy	$18.96	107.71% Upside
VNRX VolitionRx	3.00	Buy	$2.50	305.84% Upside

Current Analyst Ratings

Latest RIOT, VNRX, and NYMX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/10/2024	RIOT Riot Platforms	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$15.00 ➝ $15.50
4/5/2024	RIOT Riot Platforms	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $16.00
4/1/2024	RIOT Riot Platforms	ATB Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$20.00
3/28/2024	RIOT Riot Platforms	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$20.00
3/27/2024	VNRX VolitionRx	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$2.50
3/20/2024	RIOT Riot Platforms	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$15.00
3/18/2024	RIOT Riot Platforms	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
3/4/2024	RIOT Riot Platforms	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$20.00
2/28/2024	RIOT Riot Platforms	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$19.00 ➝ $20.00
2/23/2024	RIOT Riot Platforms	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$19.00
2/13/2024	RIOT Riot Platforms	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$19.00 ➝ $18.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NYMX Nymox Pharmaceutical	N/A	N/A	N/A	N/A	($0.01) per share	N/A
RIOT Riot Platforms	$280.70M	8.25	$1.12 per share	8.12	$9.14 per share	1.00
VNRX VolitionRx	$770K	65.66	N/A	N/A	($0.11) per share	-5.60

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NYMX Nymox Pharmaceutical	-$6.58M	-$0.04	N/A	N/A	N/A	N/A	-1,589.50%	-117.25%	N/A
RIOT Riot Platforms	-$49.47M	-$0.27	N/A	39.70	N/A	-17.62%	0.89%	0.81%	5/8/2024 (Estimated)
VNRX VolitionRx	-$35.32M	-$0.51	N/A	∞	N/A	-4,557.29%	N/A	-154.24%	5/8/2024 (Estimated)

Latest RIOT, VNRX, and NYMX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/25/2024	N/A	VNRX VolitionRx	N/A	-$0.11	-$0.11	-$0.11	$0.50 million	$0.24 million
2/22/2024	Q4 2023	RIOT Riot Platforms	-$0.29	$0.48	+$0.77	$0.48	$84.94 million	$78.83 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
NYMX Nymox Pharmaceutical	N/A	N/A	N/A	N/A	N/A
RIOT Riot Platforms	N/A	N/A	N/A	N/A	N/A
VNRX VolitionRx	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NYMX Nymox Pharmaceutical	N/A	0.19	0.19
RIOT Riot Platforms	N/A	8.33	8.33
VNRX VolitionRx	N/A	0.69	0.69

Ownership

Institutional Ownership

Company	Institutional Ownership
NYMX Nymox Pharmaceutical	1.14%
RIOT Riot Platforms	40.27%
VNRX VolitionRx	8.09%

Insider Ownership

Company	Insider Ownership
NYMX Nymox Pharmaceutical	54.00%
RIOT Riot Platforms	4.40%
VNRX VolitionRx	15.40%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
NYMX Nymox Pharmaceutical	3	90.51 million	41.64 million	Optionable
RIOT Riot Platforms	534	253.54 million	242.38 million	Optionable
VNRX VolitionRx	110	82.07 million	69.43 million	Optionable

RIOT, VNRX, and NYMX Headlines

Source	Headline
	VolitionRx (NYSE:VNRX) Now Covered by StockNews.com americanbankingnews.com - April 18 at 2:24 AM
	Zacks Small Cap Comments on VolitionRx Limited's FY2024 Earnings (NYSE:VNRX) americanbankingnews.com - April 11 at 2:40 AM
	Critical Review: VolitionRx (NYSE:VNRX) vs. Global WholeHealth Partners (OTCMKTS:GWHP) americanbankingnews.com - April 11 at 2:02 AM
	Research Analysts Set Expectations for VolitionRx Limited's FY2024 Earnings (NYSE:VNRX) marketbeat.com - April 10 at 8:28 AM
	VolitionRx Limited (NYSE:VNRX) to Post Q1 2024 Earnings of ($0.11) Per Share, Zacks Small Cap Forecasts americanbankingnews.com - April 10 at 1:22 AM
	VolitionRx Limited Forecasted to Post Q1 2024 Earnings of ($0.11) Per Share (NYSE:VNRX) marketbeat.com - April 9 at 6:09 AM
	VNRX: VolitionRx Reports 2023 Results; Distribution of Nu.Q Vet Test Expanding; Nu.Q Discover Growing; Two Key R&D Efforts in 2024/25: 1) Breakthrough Cancer Detection Method ... msn.com - April 8 at 3:37 PM
	VNRX: VolitionRx Reports 2023 Results; Distribution of Nu.Q Vet Test Expanding; Nu.Q Discover Growing; Two Key R&D Efforts in 2024/25: 1) Breakthrough Cancer Detection Method (Capture -PCR) 2) Nu.Q NET for Sepsis finance.yahoo.com - April 8 at 3:37 PM
	VolitionRx's (VNRX) Overweight Rating Reiterated at Cantor Fitzgerald marketbeat.com - March 27 at 10:15 AM
	VolitionRx (NYSE:VNRX) Releases Earnings Results marketbeat.com - March 26 at 9:17 AM
	VNRX Stock Earnings: VolitionRX Meets EPS, Misses Revenue for Q4 2023 msn.com - March 25 at 9:15 PM
	VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update prnewswire.com - March 25 at 4:10 PM
	Earnings Outlook For VolitionRX benzinga.com - March 22 at 11:30 AM
	VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update prnewswire.com - March 21 at 8:30 AM
	VolitionRx Limited: Volition appoints Dr Andrew Retter as Chief Medical Officer finanznachrichten.de - March 21 at 5:25 AM
	VolitionRx Names Andrew Retter Chief Medical Officer markets.businessinsider.com - March 19 at 11:18 PM
	Volition appoints Dr Andrew Retter as Chief Medical Officer finance.yahoo.com - March 19 at 6:17 PM
	VolitionRX Ltd money.usnews.com - March 19 at 8:16 AM
	VolitionRX Stock (AMEX:VNRX), Short Interest Report benzinga.com - February 22 at 10:12 PM
	VolitionRx stock soars after company discloses $13M in milestone payments msn.com - January 2 at 7:35 PM
	VolitionRx milestone payment 'important step forward,' says EF Hutton realmoney.thestreet.com - January 2 at 7:35 PM
	Analyzing VolitionRX Ltd (VNRX) After Recent Trading Activity knoxdaily.com - January 1 at 7:42 AM
	Volition Presents at the 5th Annual Congress of the International Liquid Biopsy Society finance.yahoo.com - November 17 at 1:08 PM
	VolitionRx to host Q3 earnings call on November 15 proactiveinvestors.com - November 8 at 2:08 PM

New MarketBeat Followers Over Time

Company Descriptions

Nymox Pharmaceutical

NASDAQ:NYMX

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.

Riot Platforms

NASDAQ:RIOT

Riot Platforms, Inc., together with its subsidiaries, operates as a bitcoin mining company in North America. The company operates through three segments: Bitcoin Mining, Data Center Hosting, and Engineering. It also provides co-location services for institutional-scale bitcoin mining companies; critical infrastructure and workforce for institutional-scale miners to deploy and operate their miners; operation of data centers; and maintenance/management of computing capacity. In addition, the company engages in the design and manufacturing of power distribution equipment and custom engineered electrical products; and electricity distribution product design, manufacture, and installation services primarily focused on large-scale commercial, and governmental customers, as well as a range of markets, including data center, power generation, utility, water, industrial, and alternative energy. The company was formerly known as Riot Blockchain, Inc. Riot Platforms, Inc. was incorporated in 1998 and is based in Castle Rock, Colorado.

VolitionRx

NYSE:VNRX

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial